Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Emergent BioSolutions Signs Deal With VaxInnate On Pandemic Influenza Vaccine

RELATED NEWS
Trade EBS now with 

Emergent BioSolutions Inc. (EBS: Quote) announced Friday that it has signed a license agreement with VaxInnate Corporation under which Emergent acquired the exclusive right to manufacture and sell VaxInnate's pandemic influenza vaccine candidate in the United States.

Emergent said VaxInnate will continue to develop its pandemic influenza vaccine candidate under its current BARDA contract and Emergent will manufacture the pandemic influenza vaccine candidate using flexible manufacturing technology.

Click here to receive FREE breaking news email alerts for Emergent BioSolutions Inc and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
After moving sharply lower at the open, stocks showed a substantial recovery attempt over the course of the trading day on Monday. The Nasdaq and the S&P 500 bounced well off the one-month intraday lows set in early trading but still closed in the red. While most Americans oppose sending ground troops into combat operations against the terrorist group known as ISIS, the results of a CNN/ORC International poll found that an even larger majority think the American military will still end up putting boots on the ground. With incumbent Sen. Kay Hagan, D-N.C., and Republican challenger Thom Tillis running nearly neck-and-neck in the North Carolina Senate race, the results of a new CNN/ORC International survey suggest that the race could be decided by the number of votes for Libertarian candidate Sean Haugh.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.